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in blood pressure rather than the de-
crease reported in several clinical studies.
Thus, it appears plausible that vascular
effects, which are a prerequisite for
edema formation, may contribute to the
overall effects of TZDs. Such effects
may be due to interference with the an-
giotensinII/AT1R or endothelin-1 path-
ways, as well as an effect on the release
of NO, all of which are regulated by
PPARγ (Marx et al., 2004).
Which perspectives do these new and
exciting results offer? First, since a direct
role for PPARγ in kidney function has now
been identified, the identification of its
target genes will allow the initiation of ge-
netic studies that may help identify individ-
uals likely to develop edema. Similarly, if
polymorphisms in the ENaC genes are as-
sociated with edema, patients at risk could
be screened before initiating TZD therapy.
Such genetic approaches should also
provide evidence for the effects of TZDs
in the kidney in humans. Second, the
identification of the site of action of
PPARγ in the kidney opens perspectives
for targeted treatment with an appropri-
ate diuretic in specific patients. Indeed,
Guan et al. (2005) proposed that treat-
ment with ameloride, a selective inhibitor
of collecting duct salt absorption acting
through ENaC, could be appropriate and
provided experimental evidence for this.
Further clinical studies should reveal
whether diuretics acting on the distal neph-
ron, such as ameloride or spironolactone,
an inhibitor of aldosterone, will be effective
in the treatment of TZD-induced edema in
patients. Although by no means definitive,
these data support the notion that TZDs
act on the distal nephron. Third, further
of PPARγ in the renal collecting duct cells
opens new perspectives for future drug de-
velopment. Indeed, significant efforts are
currently being undertaken to identify and
characterize selective PPARγ modulators
(SPPARMs) devoid of the undesirable side
effects of the currently used TZDs. Al-
though not unequivocally demonstrated,
it is likely that the fluid retention effects of
TZDs require higher doses of full agonists
and thus partial PPARγ agonism may be
another way to create an improved thera-
peutic window.
In conclusion, these recent reports
clearly demonstrate a role for PPARγ in the
kidney as a mechanism contributing to the
blood volume expansion and possibly
edema induced by TZDs. The information
will undoubtedly contribute to the identifi-
cation of patients at risk, their better man-
agement, and, possibly, the design of new,
more selective drugs devoid of side ef-
fects. Depending on the outcome of the
PROactive study, which will be the first of
these landmark trials to report at the up-
coming EASD meeting in September 2005,
it can be expected that TZD use will be
extended to prevent CVD in type 2 diabetic
patients. Since edema is the principal clin-
ical limitation for this class of drugs, further
studies on the mechanisms involved are of
major importance.
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Diabetic pancreatic β cells
ARNT all they should be
A complex network of interacting transcription factors plays a critical role in normal pancreatic β cell function, with
mutations in certain transcription factor genes known to cause diabetes. In a recent issue of Cell, Gunton et al. (2005)
demonstrate a role for the transcription factor ARNT/HIF1β (hydrocarbon nuclear receptor translocator/hypoxia-inducible
factor 1 β) in normal β cell function. ARNT expression is reduced in diabetic human islets and β cell-specific ARNT knock-
out mice show the impaired glucose tolerance and abnormal insulin secretion that are characteristic of type 2 diabetes.
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P R E V I E WFigure 1. Model of pancreatic β cell transcriptional network
This diagram shows the transcriptional network of proteins that are essential for normal β cell function. The MODY-
associated transcription factors, hepatocyte nuclear factor (HNF) 4α, HNF-1α, HNF-1β, and pancreatic homeodo-
main transcription factor (PDX-1), function in the nucleus of the β cell and regulate the expression of genes critical
to β cell function, including the insulin gene and genes involved in the transport and metabolism of glucose. Gunton
et al. (2005) demonstrate that the transcription factor ARNT/HIF1β (hydrocarbon nuclear receptor translocator/hyp-
oxia-inducible factor 1 β) is also important for normal β cell function. Experimental reductions in ARNT expression
resulted in impaired glucose-stimulated insulin secretion and reduced expression of a number of important β cell
genes including HNF-4α, insulin receptor (IR), insulin receptor substrate-2 (IRS2), Akt2, glucose-6-phospho-isom-
erase (G6PI), aldolase (Aldo), and phosphofructokinase (PFK). Members of the hypoxia-inducible transcription factor
family, such as ARNT and hypoxia-inducible factor 1α (HIF-1α), play important roles in the cellular response to
hypoxia and regulate the expression of genes such as erythropoietin (Epo) and vascular endothelial growth factor
(VEGF) in other tissues. This figure was adapted in part from a publication by Shih and Stoffel (2001).
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tType 2 diabetes results from an inability
of the pancreatic β cell to secrete suffi-
cient insulin to adequately compensate
for the prevailing degree of insulin resis-
tance. Defining the nature of the β cell
defects present in type 2 diabetes has
been difficult, in part because human
pancreatic β cells are inaccessible for di-
rect study. Pancreatic islets from dia-
betic animal models show abnormal
expression of genes involved in a multi-
plicity of β cell functions, suggesting a
key role for transcriptional regulation of
pancreatic β cell gene expression. Sup-
port for this idea comes from studies of
maturity-onset diabetes of the young
(MODY), an autosomal dominant form of
diabetes with abnormal insulin secre-
tion. Five of the six forms of MODY char-
acterized to date are due to mutations
in transcription factors that regulate the
expression of genes key to various as-
pects of β cell function (Fajans et al.,
2001), specifically HNF1α, HNF4α, HNF1β,
pancreatic duodenum homeobox (PDX)-1,
and NEUROD1/Beta2. The remaining
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tCELL METABOLISM : AUGUST 2005ODY gene encodes glucokinase, the
lycolytic enzyme that controls the first
ate-limiting step in β cell glucose me-
abolism. Humans with mutations in the
ive transcription factors that cause
ODY demonstrate reduced glucose-
nduced insulin secretion. Animal mod-
ls in which the expression of these
ranscription factors have been per-
urbed suggest that these factors regu-
ate the expression of the insulin and
ther genes that determine key β cell
unctions including glucose uptake and
etabolism, depolarization of the β cell
embrane in response to glucose, and
rowth and survival of the β cell (Dukes
t al., 1998; Gupta et al., 2005; Johnson
t al., 2003). It has been proposed that
ene expression in the β cell is con-
rolled by a complex network of tran-
cription factors, including those re-
ponsible for the development of MODY
Shih and Stoffel, 2001).
In a study just published in Cell (Gun-
on et al., 2005), the authors suggest
hat another transcription factor, aryl hy-
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trocarbon nuclear receptor translocator
ARNT) (also known as hypoxia-induc-
ble factor 1 β or HIF1β), not previously
nown to be active in the β cell, plays a
ey role in this tissue and could poten-
ially mediate β cell dysfunction in type
diabetes. Pancreatic islets were ob-
ained from five patients with type 2 dia-
etes and from nondiabetic controls,
nd β cell gene expression was mea-
ured by oligonucleotide microarray and
y real-time PCR. This screen detected
educed expression of multiple genes in-
olved in β cell function, including cer-
ain of the MODY genes, genes involved
n the uptake and metabolism of glu-
ose, and genes within the β cell insulin
ignaling pathway. The most significant
ifference that was observed, however,
as in ARNT, which demonstrated a re-
uction in expression of approximately
0%. To define the functional conse-
uences of these changes, the investi-
ators used siRNA to reduce ARNT
xpression in the insulin-secreting insu-
inoma cell line Min6. This led to im-
aired glucose-induced insulin secretion
nd recapitulated many of the reduc-
ions in gene expression seen in the is-
ets from diabetic humans, with affected
enes including HNF4α, G6PI, PFK, in-
ulin receptor, IRS-2, and Akt2. β cell-
pecific ARNT knockout mice (β-ARNT)
ere produced in order to characterize
he in vivo consequences of reduced
RNT expression. The β-ARNT mice ex-
ibited abnormal glucose tolerance, im-
aired insulin secretion, and a pattern of
educed β cell gene expression that was
imilar to that seen in human diabetic is-
ets and Min6 cells lacking ARNT ex-
ression.
What is known about ARNT? How
ight expression of this transcription
actor be related to normal β cell func-
ion, and could alterations in its expres-
ion play a role in β cell dysfunction in
iabetes? ARNT (HIF-1) is a member of
he basic helix-loop-helix Per/AhR/ARNT/
im (PAS) family of transcription factors
nd is necessary for normal embryonic
evelopment. ARNT expression and tran-
criptional activity increase in response
o hypoxia, and ARNT’s known targets
nclude erythropoietin, glucose transpor-
ers, glycolytic enzymes, and vascular
ndothelial growth factor (Semenza, 1999).
ts role in cellular and systemic responses
o hypoxia and tumor progression has
een extensively studied, and it appears
o play a critical role in the maintenance79
P R E V I E Wof respiratory and metabolic homeosta-
sis. Interestingly, the mouse knockout of
the aryl hydrocarbon receptor (AhR), a
member of the PAS family and dimeriza-
tion partner to ARNT, was found to have
impaired glucose tolerance with aging
(Thackaberry et al., 2003). In addition,
ARNT has been reported to physically
interact with HNF4α, the transcription
factor that is mutated in type 1 MODY
(Tsuchiya et al., 2002). Furthermore, the
Per-Arnt-Sim (PAS) kinase pathway has
been shown to stimulate preproinsulin
and PDX-1 gene expression in rodent is-
lets (da Silva Xavier et al., 2004).
Thus, Gunton et al. (2005) have pro-
vided convincing evidence that a reduc-
tion in ARNT expression has important
negative consequences for β cell func-
tion, including impaired glucose-induced
insulin secretion and reduced expres-
sion of a number of important β cell
genes including HNF-4α, G6PI, PFK, in-
sulin receptor, IRS-2, and Akt2. It there-
fore appears appropriate to add ARNT
as a new player in the network of tran-
scription factors that regulate normal β
cell function (Figure 1). Based on the
data presented, ARNT may be viewed
as exerting its effects upstream of
HNF4α, since levels of HNF4α were
consistently reduced when ARNT ex-
pression was reduced. How ARNT ex-
pression relates to other members of
this transcriptional network awaits addi-
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ownstream targets.
Do the presented data allow us to
scribe an important causal role for
RNT in the pathogenesis of type 2 dia-
etes in humans? Evidence for linkage
etween genetic variation in the ARNT
ene and susceptibility to diabetes would
ake for a convincing argument. Dem-
nstrating that ARNT expression is influ-
nced by one or more of the metabolic
hanges that characterize diabetes or
lucose intolerance, such as hypergly-
emia or increased levels of free fatty
cids, would also more directly connect
ltered ARNT expression and diabetes.
lternatively, the present findings could
e the first clue to identifying an entirely
ovel mechanism whereby environmen-
al stimuli may lead to β cell dysfunction
nd diabetes. Whatever the final out-
ome of these studies, this work has de-
ined a novel role for ARNT in the tran-
criptional regulation of pancreatic β cell
ene expression, has provided impor-
ant new information about diabetic hu-
an islets, and has suggested ARNT as
potential player in the pathogenesis of
he β cell dysfunction in type 2 diabetes.
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